Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q3 2026 › vs Q2 2026
Ironwood Pharmaceuticals (IRWD) Q3 2026 vs Q2 2026 (quarter over quarter)
Ironwood Pharmaceuticals's revenue rose $20.0M (+18%) from $113M in Q2 2026 to $133M in Q3 2026. Operating margin 70.0% against 70.2% (-0.2 pts).
Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%, net earnings $59.8M, operating cash flow $67.4M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 70.0% | 70.2% | -0.2 pts |
| Net margin | 45.0% | 45.4% | -0.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $133M | $113M | $20.0M | +18% |
| Operating profit | $93.1M | $79.3M | $13.8M | +17% |
| Costs & expenses | $39.9M | $33.7M | $6.2M | +18% |
| Pre-tax earnings | $87.6M | $73.7M | $13.9M | +19% |
| Other expense, net | $5.5M | $5.6M | −$38K | -0.7% |
| Research & development | $28.4M | $22.4M | $5.9M | +26% |
| SG&A | $11.6M | $11.3M | $241K | +2% |
| Net earnings | $59.8M | $51.3M | $8.5M | +17% |
| Income tax | $27.8M | $22.4M | $5.3M | +24% |
| Depreciation | $459K | $457K | $2K | +0.4% |
| Share-based compensation | $4.3M | $3.2M | $1.1M | +33% |
| Working capital & other | $2.8M | $3.3M | −$479K | -15% |
| Operating cash flow | $67.4M | $58.3M | $9.1M | +16% |
Questions
How much did Ironwood Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Ironwood Pharmaceuticals's revenue rose $20.0M (+18%) from $113M in Q2 2026 to $133M in Q3 2026. Operating margin 70.0% against 70.2% (-0.2 pts).